Clinical trials: Anti-coagulation Therapy
Osteoperosis, Femoral Neck Fractures
Monitoring Bleeding of Patients Using NOAC Anticoagulation Therapy in Proximal Femoral Fracture Internal Fixation Surgery Without Waiting. We Measure Bleeding in Surgery and the Levels of Noac Drug in Blood. We Will Try to Compare to Regular Pateints Later
until today we waited at least 24 hours before surgery of femoral neck fractures in patients who take anticouagolation . in our new reasearch we belive that patients who take NOAC can go under surgery earlier with minimal risk
- Conditions
- Osteoperosis, Femoral Neck Fractures, Anticoagulant Therapy
- Trial name
- NCT06644976
- Testing
- femoral neck CRIF
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Meir Hospital, Kfar Saba, Israel
Colon Polyp
Prophylactic Clip Application for Colon Polypectomy in Patients With Anticoagulation
There have been very limited evidence about the bleeding complication during colon polypectomy for the patients taking warfarin.
- Trial name
- NCT02120170
- Testing
- Colon polypectomy
- Where
- South Korea
- Volunteers
- 356 people
- Sponsor
- Soonchunhyang University Hospital
Cerebral Vein Thrombosis, Deep Vein Thrombosis
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related venous thrombosis in cancer patients who have completed anticoagulation therapy.
- Conditions
- Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT03080883
- Testing
- Apixaban
- Where
- 32 sites in United States
- Volunteers
- 370 people
- Sponsor
- Academic and Community Cancer Research United
Renal Replacement Therapy
A Clinical Study to Evaluate the Efficacy, Safety and PK/PD Profiles of Anticoagulation of HSK36273 for Injection in Continuous Renal Replacement Therapy Subjects
This study is divided into Stage I and Stage II. It is planned to include 156 subjects who need CRRT treatment for more than 48 hours.
- Trial name
- NCT05602129
- Testing
- HSK36273, Heparin sodium
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Self Management of Oral Anticoagulation With VKA Therapy
Clinical Outcomes From Patient Self-management of Antivitamin K Treatment
ORION is a retrospective, observational, one center study to evaluate the incidence of complications (both thromboembolic and bleedings) in a cohort of patients receiving Vitamin K antagonists (VKA) under a self-management…
- Trial name
- ORION (NCT03532724)
- Testing
- Patient Self-Management of VKA therapy
- Where
- Spain
- Volunteers
- 927 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Immune Thrombocytopenia, Treatment
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia
To evaluate the safety and efficacy of Obinutuzumab in the treatment of immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment.
- Trial name
- 2023CD20ITP (NCT05995054)
- Testing
- Obinutuzumab Injection [Gazyva]
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Kidney Injury
Citrate Versus Heparin Anticoagulation in Continuous Venovenous Hemofiltration
The purpose of this study is to compare citrate regional anticoagulation with systemic heparinization in continuous venovenous hemofiltration.
- Trial name
- CASH-CVVH (NCT00209378)
- Testing
- regional anticoagulation with citrate, HfCitPre
- Where
- 9 sites in Netherlands
- Volunteers
- 139 people
- Sponsor
- Universitair Ziekenhuis Brussel
Acute Coronary Syndrome, Atrial Fibrillation
APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF
It is hypothesised that a dual therapy strategy by oral anticoagulation with the new Factor-Xa-inhibitor apixaban plus clopidogrel is superior to a triple therapy regimen with phenprocoumon plus acetylsalicylic acid (ASA) and…
- Conditions
- Acute Coronary Syndrome, Atrial Fibrillation, Coronary Artery Disease
- Trial name
- APPROACH (NCT02789917)
- Testing
- Dual Therapy, Triple Therapy
- Where
- 16 sites in Germany
- Volunteers
- 403 people
- Sponsor
- LMU Klinikum
Atrial Fibrillations, Heart Valve Prostheses
What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
The optimal antithrombotic therapy for patients with atrial fibrillation (AF) with a CHA2DS2-VASc score ≥1 with concomitant acute coronary syndrome (ACS) or revascularisation by percutaneous coronary intervention (PCI) with…
- Conditions
- Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes, Coronary Artery Diseases
- Trial name
- WOEST 2 (NCT02635230)
- Testing
- Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 2,200 people
- Sponsor
- R&D Cardiologie
Anticoagulation, Left Ventricular Assist Device
Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)
The purpose of this observational study is to obtain multi-center data on HeartMate II (HMII) patients managed with reduced anticoagulation or anti-platelet regimes, and the incidence of thrombotic and bleeding adverse events…
- Trial name
- TRACE (NCT01477528)
- Where
- 18 sites in United States, Austria and 3 more
- Volunteers
- 201 people
- Sponsor
- Abbott Medical Devices
Intracranial Arteriosclerosis, Stroke
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular…
- Trial name
- CAPTIVA (NCT05047172)
- Testing
- Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin
- Where
- 114 sites in United States
- Volunteers
- 1,683 people
- Sponsor
- University of Florida
Atrial Fibrillation, Deep Vein Thrombosis
A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics
Caribbean Hispanics are a population with a disproportionately high prevalence of cardio-metabolic disorders but with a limited expectation of benefits from current pharmacogenetic algorithms derived mainly in subjects of…
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Cardiac Valvular Insufficiency, Coagulopathies
- Trial name
- NCT02345356
- Testing
- Genotype-guided, Standard-of-Care
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- University of Puerto Rico
Anticoagulation in Pregnancy
Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy
A prospective, randomized, longitudinal, open label, parallel group clinical trial was designed to compare the proportions of failure to reach INR target 2.5-3.5 with either: small dose warfarin (<5 mg/day) or phenindione (<100…
- Trial name
- NCT01758640
- Testing
- Warfarin, phenindione
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Yasser Elnahas
Acute Ischemic Stroke
Second Enhanced Control of Hypertension and Thrombectomy Stroke Study (ENCHANTED2)
ENCHANTED2 is an international, multicenter, prospective, randomised, open, blinded end-point assessed (PROBE) trial, to assess different approaches to manage blood pressure (BP) in acute ischemic stroke (AIS) patients who have…
- Trial name
- ENCHANTED2 (NCT04140110)
- Testing
- Intensive BP lowering
- Where
- China
- Volunteers
- 816 people
- Sponsor
- The George Institute for Global Health, China
Immune Thrombocytopenia, Treatment
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
This randomized, open-label study aim to compare the efficacy and safety of rituximab combining anti-CD38 monoclonal antibody with rituximab in ITP patients.This study will be conducted in ITP patients who had not responded to or…
- Trial name
- NCT07234019
- Testing
- Daratumumab（Anti-CD38 Monoclonal Antibody）, Rituximab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Non-valvular Atrial Fibrillation
Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
This study is designed to gain real-world clinical data on the peri- and post-procedural usage of anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation (NVAF) undergoing successful…
- Trial name
- ENCOURAGE-AF (NCT04519944)
- Testing
- Edoxaban
- Where
- 66 sites in Germany
- Volunteers
- 666 people
- Sponsor
- Daiichi Sankyo
Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
The goal of this observational study is to learn the safety and efficacy of edoxaban and rivaroxaban in Chinese population with the age range from 18 to 80 years who take edoxaban or rivaroxaban to treat their cerebral venous…
- Conditions
- Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders, Anticoagulation Treatment, Anticoagulant Therapy
- Trial name
- NCT06947707
- Where
- China
- Volunteers
- 1,486 people
- Sponsor
- Xuanwu Hospital, Beijing
Endstage Renal Disease, Direct Oral Anticoagulants (DOACs)
Effect of Apiban Therapy on AVF Maturation in ESRD Patients
End-stage renal disease (ESRD) is a growing global health burden, and the creation of a native arteriovenous fistula (AVF) is the gold standard for vascular access in patients requiring hemodialysis [1].
- Conditions
- Endstage Renal Disease, Direct Oral Anticoagulants (DOACs), Arteriovenous Fistula, Arteriovenous Fistula Occlusion
- Trial name
- NCT07559942
- Testing
- Apixaban
- Where
- Pakistan
- Volunteers
- 190 people
- Sponsor
- Combined military hospital lahore
Venous Thrombosis, Neoplasms
Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
The primary purpose of this study is to determine the optimal duration of anticoagulation therapy (6 months versus 18 months) with direct oral anticoagulant (DOAC) for cancer-associated low-risk pulmonary embolism patients.
- Conditions
- Venous Thrombosis, Neoplasms, Anticoagulants
- Trial name
- ONCO PE (NCT04724460)
- Testing
- Long DOAC, Short DOAC
- Where
- Japan
- Volunteers
- 179 people
- Sponsor
- Takeshi Morimoto
Aortic Valve Disease, Myocardial Infarction
Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation
At present, a variety of antithrombotic regimens are prescribed in the early postprocedure period after transcatheter aortic valve implantation (TAVI).
- Conditions
- Aortic Valve Disease, Myocardial Infarction, Stroke, Bleeding
- Trial name
- POPular-TAVI (NCT02247128)
- Testing
- Aspirin + clopidogrel, Aspirin monotherapy, OAC + clopicogrel
- Where
- 17 sites in Belgium, Czechia and 2 more
- Volunteers
- 1,016 people
- Sponsor
- St. Antonius Hospital